CAMELLIA-TIMI 61 was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.
MAIN RESULTS:
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

PRESENTATIONS
CV Safety & Efficacy of Lorcaserin in Overweight and Obese Patients-Primary Results from CAMELLIA (Bohula ESC 2018)
Primary Results (Bohula, ESC 2018)
Renal Outcomes (Bohula, AHA 2018)
PUBLICATIONS
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial